Literature DB >> 25349636

Cross interaction of dopaminergic and adrenergic systems in neural modulation.

Saobo Lei1.   

Abstract

Catecholamines including dopamine (DA) and norepinephrine (NE) are widely distributed in the body and exert extensive physiological functions by serving as neurotransmitters or neuromodulators. Alterations in the level of these two catecholamines underlie many neurological and psychiatric disorders. The pharmacology of both DA and NE including their individual receptors, signaling mechanisms, agonists and antagonists has been extensively studied. Whereas the traditional idea is that neurotransmitters specifically interact with their receptors, there is compelling evidence indicating that DA and NE exert biological actions by activating the receptors of other family in a variety of regions. Here, I review the experimental evidence showing cross activation of each other's receptors by these two catecholamines. This promiscuous interaction may represent a novel way for catecholamines to exert their functions.

Entities:  

Keywords:  Catecholamine; G protein-coupled receptor; dopamine; norepinephrine; receptor; transmitter

Year:  2014        PMID: 25349636      PMCID: PMC4208734     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  22 in total

1.  Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses.

Authors:  Haripriya Shankar; Swaminathan Murugappan; Soochong Kim; Jianguo Jin; Zhongren Ding; Kevin Wickman; Satya P Kunapuli
Journal:  Blood       Date:  2004-05-13       Impact factor: 22.113

2.  Selectivities of some agonists acting at alpha 1- and alpha 2-adrenoreceptors in the rat vas deferens.

Authors:  J A Leedham; J N Pennefather
Journal:  J Auton Pharmacol       Date:  1986-03

3.  Nociceptin/orphanin FQ suppresses the excitability of neurons in the ventromedial nucleus of the hypothalamus.

Authors:  Melissa J Chee; Christopher J Price; Michael A Statnick; William F Colmers
Journal:  J Physiol       Date:  2011-04-18       Impact factor: 5.182

Review 4.  The physiology, signaling, and pharmacology of dopamine receptors.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

5.  Neuropeptide Y activates a G-protein-coupled inwardly rectifying potassium current and dampens excitability in the lateral amygdala.

Authors:  Ludmila Sosulina; Gerrit Schwesig; Gerald Seifert; Hans-Christian Pape
Journal:  Mol Cell Neurosci       Date:  2008-08-27       Impact factor: 4.314

6.  Effect of dopamine on adenosine 3',5'-cyclic monophosphate levels in human platelets.

Authors:  G Anfossi; P Massucco; E Mularoni; L Mattiello; F Cavalot; S Burzacca; M Trovati
Journal:  Gen Pharmacol       Date:  1993-03

7.  Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation.

Authors:  Yan Lin; David Quartermain; Adrian J Dunn; David Weinshenker; Eric A Stone
Journal:  Synapse       Date:  2008-07       Impact factor: 2.562

Review 8.  A top-down perspective on dopamine, motivation and memory.

Authors:  Anthony G Phillips; Giada Vacca; Soyon Ahn
Journal:  Pharmacol Biochem Behav       Date:  2007-11-28       Impact factor: 3.533

9.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors:  A Enjalbert; J Bockaert
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

10.  Activation of beta3-adrenoceptors by exogenous dopamine to lower glucose uptake into rat adipocytes.

Authors:  T L Lee; C T Hsu; S T Yen; C W Lai; J T Cheng
Journal:  J Auton Nerv Syst       Date:  1998-12-11
View more
  17 in total

Review 1.  Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.

Authors:  Safwan K Elkhatib; Adam J Case
Journal:  Pharmacol Res       Date:  2019-06-06       Impact factor: 7.658

Review 2.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

Authors:  Irene Sebastianutto; Elise Goyet; Laura Andreoli; Joan Font-Ingles; David Moreno-Delgado; Nathalie Bouquier; Céline Jahannault-Talignani; Enora Moutin; Luisa Di Menna; Natallia Maslava; Jean-Philippe Pin; Laurent Fagni; Ferdinando Nicoletti; Fabrice Ango; M Angela Cenci; Julie Perroy
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  [Comparison of the outcomes between open and hybrid approaches in the treatment of thoracoabdominal aortic aneurysms repair].

Authors:  W H Li; W Li; X M Zhang; Q L Li; Y Jiao; T Zhang; J J Jiang; X M Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-02-18

5.  Optimising the management of children with concomitant bladder dysfunction and behavioural disorders.

Authors:  Dilharan D Eliezer; Christopher Lam; Angela Smith; John Mithran Coomarasamy; Naeem Samnakay; Malcolm R Starkey; Aniruddh V Deshpande
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-06-29       Impact factor: 5.349

6.  Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist.

Authors:  Marta Sánchez-Soto; Alessandro Bonifazi; Ning Sheng Cai; Michael P Ellenberger; Amy Hauck Newman; Sergi Ferré; Hideaki Yano
Journal:  Mol Pharmacol       Date:  2016-02-03       Impact factor: 4.436

7.  Effects of electroacupuncture on cognitive function in rats with Parkinson's disease.

Authors:  Xiang Shen; Yan-Ying Xie; Chen Chen; Xiao-Ping Wang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-12-13

Review 8.  Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions.

Authors:  Mihai V Putz; Corina Duda-Seiman; Daniel Duda-Seiman; Ana-Maria Putz; Iulia Alexandrescu; Maria Mernea; Speranta Avram
Journal:  Int J Mol Sci       Date:  2016-07-08       Impact factor: 5.923

9.  Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors.

Authors:  Hubert J Sijben; Wieke M van Oostveen; Peter B R Hartog; Laura Stucchi; Andrea Rossignoli; Giovanna Maresca; Lia Scarabottolo; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

10.  Aripiprazole as a treatment option for clozapine-induced enuresis.

Authors:  Pradeep Palaniappan
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.